Parameter	Everolimus vs. Cabozantinib, $		Everolimus vs. Nivolumab, $		Everolimus vs. Axitinib, $
	Low Value	High Value	Low Value	High Value	Low Value	High Value
Base case	21,338	–	64,570	–	35,012	–
Everolimus PFS, bounds of 95% CI	14,752	33,284	20,261	Everolimus has lower costs and greater efficacy	14,344	Everolimus has lower costs and greater efficacy
Comparator PFS, bounds of 95% CI	28,336	13,387	Everolimus has lower costs and greater efficacy	31,408	Everolimus has lower costs and greater efficacy	7,179
Everolimus OS, bounds of 95% CI	22,901	19,343	72,906	53,933	40,014	28,630
Comparator OS, bounds of 95% CI	20,400	23,510	43,841	64,570	26,395	42,834
Everolimus WAC price, ±25%	31,019	11,658	116,200	12,941	65,990	4,035
Comparator WAC price, ±25%	15,122	27,554	1,287	127,854	Axitinib has lower costs and greater efficacy	71,203
AWP prices	26,026	–	73,894	–	39,183	–
Everolimus treatment duration, ±25%	31,899	17,818	120,893	45,796	68,806	23,748
Comparator treatment duration, ±25%	5,296	21,338	44,644	64,570	1,605	35,012
Other postprogression costs, ±25%	21,373	21,303	64,478	64,663	35,096	34,929
Duration of third-line treatment, ±50% or ±25%	21,854	21,338	52,950	64,570	36,662	35,012
Cost of adverse events, ±25%	21,323	21,354	65,975	63,166	33,762	36,262

Note: All costs are in 2016 U.S dollars.

AWP = average wholesale price; CI = confidence interval; OS = overall survival; PFS = progression-free survival; WAC = wholesale acquisition cost.